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Background: Different psychotherapeutic treatments for schizophrenia are delivered in 
groups. However, little is known about the effectiveness of these groups for people with 
schizophrenia across different treatments with varying therapeutic orientations. This review 
aimed to i) estimate the effect of different group psychotherapeutic treatments for 
schizophrenia and ii) to explore whether any overall ‘group effect’ is moderated by 
treatment intensity, diagnostic homogeneity and therapeutic orientation. Methods: A 
systematic search of randomised controlled trials exploring the effectiveness of group 
psychotherapeutic treatments for people with schizophrenia was conducted. Random-effect 
meta-analyses on end-point symptom scores compared group psychotherapeutic 
treatments against treatment-as-usual and active sham groups. Findings on social 
functioning were described narratively and meta-regression analyses on group 
characteristics were carried out. Results: Thirty-four eligible trials were included. A small-to-
moderate significant between-group difference in favour of group psychotherapeutic 
treatments was found for negative symptom scores (SMD = -0.37, 95%CI:-0.60,-0.14, p<0.01, 
I²=59.8%) only when compared to treatment-as-usual, not active sham groups. Improved 
social functioning was reported as a treatment outcome in the majority of studies compared 
to treatment-as-usual. The ‘group effect’ on negative symptoms was positively related to 
‘treatment intensity’ (Beta=0.32, SE=0.121, P<0.05). Conclusion: Group psychotherapeutic 
treatments can improve negative symptoms and social functioning deficits in the treatment 
of schizophrenia. The effect occurs across different treatments and appears to be non-
specific. Future research should identify the underlying mechanisms for the positive effect of 
participating in groups and explore how they can be maximised to increase the therapeutic 
benefit.  
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Introduction 
In accordance with guidelines from the National Institute for Health and Care 
Excellence in the United Kingdom (UK) [1] and the Schizophrenia Patient Outcomes Research 
Team in the United States (US) [2], psychotherapeutic treatments are widely regarded as a 
necessary intervention for  schizophrenia. In particular, there has been a growing interest in 
the development and delivery of psychotherapeutic treatments in a group format for this 
population [3].  
From an economic perspective, a group setting is seen as a useful approach, as it 
allows for one therapist to treat several people at the same time [4]. From a clinical 
perspective, group psychotherapeutic treatments are also believed to offer social 
advantages relevant to this population [4-8], who often have smaller social networks and 
less satisfactory interpersonal relationships compared to a healthy population [9]. Seminal 
work on group therapeutic processes [10] (including group cohesion, instillation of hope,  
interpersonal learning and sharing of information) supports the notion that the group 
setting can be utilized as an agent of change in group psychotherapeutic treatments.  
Evidence from randomised controlled trials on group cognitive behavioural therapy 
(CBT) [6], group social skills training [11], group music therapy [12] and group psycho-
education [13], suggest that group psychotherapeutic treatments, with different therapeutic 
orientations, can be effective in improving a number of clinical outcomes for people with 
schizophrenia. In their review of controlled studies for schizophrenia conducted between 
1986 and 2006, Segredou and colleagues [8] found that, descriptively, all of the 23 they 
identified showed a positive effect on either symptom or skills outcomes. 
In the treatment of positive symptoms, including hallucinations and delusions, a 
group format has been suggested to provide an opportunity for participants to share 
experiences and reflect on similarities, which in turn aid restructuring of false beliefs [7, 14, 
15]. In the treatment of negative symptoms, such as lack of speech, social withdrawal, 
blunted affect and social functioning deficits, it has been argued that group members serve 
as models and reinforcers for each other, which, in turn, can help the development of 
relationships [11, 16]. Improved understanding on how to treat negative symptoms is of 
particular importance, given these symptoms are more resistant to medication than positive 
symptoms [17], and highly related to poor social functioning [18] and poor quality of life 
[19]. 
Despite the potential cost benefits and clinical advantages of a group setting, little 
methodologically robust research has explored whether group psychotherapeutic 
treatments have a benefit for people with schizophrenia [20-22], and whether they are 
effective across specific therapeutic orientations [23]. At present too few studies are 
available to test the effectiveness of group treatments as compared to individual treatments 
for each psychotherapeutic treatment for schizophrenia [22]. Furthermore, whilst attempts 
have been made to summarise findings from controlled trials exploring the effectiveness of 
group psychotherapeutic treatments for schizophrenia [8, 22, 24, 25], the conclusions from 
these studies are limited in scope. For example, Segredou and colleagues’ most recent 
attempt [8] does not included evidence from nonverbal creative group arts therapies 
(including music therapy, body psychotherapy and art therapy) which have been shown to 
be effective in reducing negative symptoms [1]. Furthermore, their findings are limited to a 
descriptive analysis of the literature.  
To date, no attempt has been made to pool statistically the existing evidence using 
meta-analytical techniques. Consequently it is unclear whether group psychotherapeutic 
treatments have an effect across different treatment models for schizophrenia with varying 
therapeutic orientations. This review therefore aimed to establish whether there is an 
overall ‘group effect’ across a range of group psychotherapeutic treatments as compared to 
treatment-as-usual (TAU) [26]. If people with schizophrenia benefit from a non-specific 
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‘group experience’, one would expect to see clinical improvements in participants across a 
range of group psychotherapeutic treatments. If this effect was in fact due to processes in 
the ‘group’, it might not be apparent when compared to an active sham group [1]. In the 
literature, active sham groups are defined as a group condition aimed at controlling for 
nonspecific effects of the ‘group’ (for example therapist attention, therapeutic rationale and 
therapeutic alliance), and strictly does not involve any of the unique psychotherapeutic 
techniques under investigation [27, 28]. We therefore also assessed whether there is an 
effect of group psychotherapeutic approaches with active sham groups. Finally, we aimed to 
explore what group characteristics contribute to any potential group effect. In particular, we 
considered the therapeutic orientation, number of sessions/length of intervention [22] 
and/or diagnostic homogeneity [7], as potentially important factors for the impact of group 
psychotherapeutic treatments [8, 24]. 
 
Methods 
Search Strategy: 
  A protocol was developed using the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses statement (PRISMA) [29]. The electronic databases searched 
included PsychINFO (1806 to March 2014), Medline (1946 to March 2014), Embase (1974 to 
March 2014), and AMED (1985 to March 2014). MESH and text word search terms relating 
to ‘group psychotherapeutic therapies’ AND ‘randomised controlled trials’ AND 
‘schizophrenia’ (see online suppl. Table 1 for Medline search terms) were used for each 
database. Search terms were modified for each database. Where outcome data were not 
fully reported, first and second authors were contacted via email requesting any missing 
information. Hand-searching of the following key journals was conducted: Group Therapy, 
Behavioural Group Therapy, Clinical Psychologist, Group Analysis, International Library of 
Group Analysis and the Journal of Contemporary Psychotherapy. A grey literature search of 
the Cochrane database, and websites including Health Technology Assessment, National 
Institute of Mental Health, Wellcome Trust and Medical Research Council, was also 
conducted. Additionally, studies cited in relevant reviews on psychotherapeutic treatments 
for schizophrenia were hand-searched. 
 
Eligibility Criteria: 
Studies at the title and abstract phase were screened against the following inclusion 
criteria: (1) randomised controlled trial; (2) psychotherapeutic treatments provided in 
treatment condition; (3) included participants with a diagnosis of schizophrenia and related 
disorders. Studies were excluded if they (1) involved individualised treatment; (2) involved 
family therapy and/or family intervention; (3) included participants aged 16 years or below. 
Studies that were only abstract publications and/or protocols were not included.  
At the full paper review stage, studies were further excluded against the following 
exclusion criteria: (1) a sample with fewer than 85% of participants diagnosed with 
schizophrenia, schizotypal, schizoaffective and/or other non-affective psychotic disorders 
outlined in the Diagnostic Statistical Manual and International Classification of Diseases;  (2) 
did not measure either symptoms of schizophrenia (either positive, negative, general or 
total symptoms) or social functioning; (3) did not make a clear reference to a group format 
in the treatment condition; (4) was not published in a language using Latin-based characters; 
(5) control condition was delivered as a group psychotherapeutic treatment, rather than an 
active sham group (i.e. active discussion group, support group, counselling group,  
occupational therapy group, or problem solving discussion group) or TAU; where ‘waitlist 
control group’ (no treatment offered until the intervention condition has received their 
treatment) and ‘standard psychiatric care’ are considered as treatment-as-usual. 
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Study selection and data extraction 
The first author (SO) conducted the initial screening of all the titles and abstracts 
and all studies at the full paper review phase. The second author (CB) re-extracted 50% of 
the studies at full paper review and 20% of abstracts, randomly selected using a random 
number generator. Any ambiguity was resolved with the third author (SP). All included 
studies were independently extracted by two reviewers (SO and CB) using a structured 
format (see online suppl. Table 2). The Cochrane risk of bias tool was used to assess the 
studies [30]. It was agreed by all authors to exclude ‘blinding of personnel’ category, given 
that in trials examining the effectiveness of group psychotherapeutic treatments it is not 
possible to keep participants blind to their treatment allocation. ‘High’ risk studies were 
identified as those that scored ‘high risk’ for at least 4 of the 6 categories prior to data 
extraction.  
 
Outcomes: 
The primary outcome was end of treatment mean symptom scores (including 
positive, negative, general and/or total symptom scores), measured as a continuous 
variable. As measured by the Positive and Negative Symptom Scale (PANSS [31]), positive 
symptoms include delusions, grandiosity, suspiciousness, hostility and hallucinations;  
negative symptoms include emotional withdrawal, poor rapport, difficulty in abstract 
thinking, blunt affect and social withdrawal; general symptoms include anxiety, depression,  
insight and guilt; while total symptom scores are the sum of positive, negative and general 
symptoms. Original authors’ definitions of symptoms were followed, rather than a 
predefined operationalised definition.  Social functioning scores were measured as a 
secondary outcome and examined descriptively. 
 
Data Analysis: 
For each study, means and standard deviations were extracted. Standard mean 
differences (SMDs) with 95% confidence intervals (CIs) were calculated from the data 
extracted. Data were pooled using a random-effects meta-analysis in STATA Version 12. End-
point scores from both the treatment and control conditions were used to assess the impact 
of group psychotherapeutic treatments on symptoms of schizophrenia. Data were pooled in 
such a way that a SMD less than 0 favoured the treatment condition. Heterogeneity was 
assessed visually and by the I² statistic [32].  
The first set of meta-analyses explored group psychotherapeutic treatments 
compared with TAU for positive, negative, general and total symptom scores. The second set  
of meta-analyses explored group psychotherapeutic treatments compared to active sham 
groups for positive, negative, general and total symptom scores. Planned sensitivity analyses 
were conducted to explore the robustness of the results. In these analyses, studies with a 
high risk of bias and studies where baseline mean symptom scores varied across the 
treatment and control condition were excluded.  
A post-hoc meta-regression analysis was used to explore what factors were driving 
significant group effects found across the main meta-analyses and planned sensitivity 
analyses.  A meta-regression analysis was therefore only conducted on studies that 
compared a group psychotherapeutic treatment to TAU and not active sham groups. The 
first meta-regression analysis explored the effect of therapeutic orientation, by 
dichotomising psychotherapeutic treatments as a) nonverbal arts therapies (including music 
therapy, body-oriented psychotherapy and art therapy) vs non-arts therapies and b) as 
cognitive-behavioural approaches (including cognitive-behavioural social skills training, and 
compensatory cognitive training) vs other therapeutic approaches. The second meta-
regression analysis explored the effect of treatment ‘intensity’; calculated as a continuous 
variable from duration of session (in hours) multiplied by the number of sessions offered in 
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the treatment. A log transformation was conducted on this variable to ensure this variable 
was normally distributed. The third meta-regression analysis explored the effect of 
‘diagnosis’ as a dichotomised variable, comparing studies that included ‘schizophrenia’ and 
‘schizophrenia and related disorders’.  
  Due to the varied range of assessments used to measure social functioning, it was 
decided a-prior to not conduct a meta-analysis on this outcome. As outlined by Higgins and 
colleagues [30], a meta-analysis should only be conducted if outcomes share similar clinical 
characteristics. Instead, outcomes on social functioning deficits were discussed descriptively 
in a narrative synthesis, which included a description of statistical outcomes and author 
conclusions.  
 
Results  
Search Results 
5078 studies were identified in the electronic database search. Following the 
exclusion of duplications (n=1962) and removal of studies at the title screening phase 
(n=1564), 1552 abstract articles were reviewed (see online suppl. Fig. 1). Of the 324 studies 
identified for full paper review, 34 studies were included. Seven studies [33-39] used the 
data from three data sets, one study [40] included data from two separate trials, and one 
study [41] had two control arms. Hence in total, 32 data sets were included in the final 
meta-analysis.  
 
Study Characteristics  
 The study characteristics of the studies from which the 32 data sets were included 
are summarised in online suppl. Table 3. In total, 13 data sets compared a group 
psychotherapeutic treatment to an active sham group [37, 39, 41-51], and 19 data sets 
compared a group psychotherapeutic treatment to treatment-as-usual [7, 12, 13, 34, 40, 41, 
52-63]. 31% of the interventions were cognitive-behavioural approaches (including 
cognitive-behavioural social skills training, and compensatory cognitive training), 19% came 
under the umbrella term non-verbal arts therapies (including music therapy, body-oriented 
psychotherapy and art therapy); the remaining 50% included a range of therapeutic 
orientations such as cognitive remediation therapy, psycho-education, and integrated 
approaches. These approaches were varied in terms of their therapeutic focus and 
therapeutic outcome (see online suppl. Table 4); including positive symptoms (13%), social 
functioning (22%), cognitive functioning (22%) and negative symptoms (9%), a range of 
outcomes (22%) or outcomes that did not fit in any of these categories (22%). The most 
common measures of symptoms was the PANSS; 81%, 63%, 92.9% and 68.4% for positive, 
negative, general and total symptom scores respective (see online suppl. Table 5). 22 studies 
(71%) were conducted in an outpatient setting, 12 studies (38%) stated use of an intention-
to-treat design and nine studies (28%) included a sample size calculation. The average 
follow-up rate was 8% for studies that compared a group psychotherapeutic treatment with 
an active sham group, and 7% for studies that compared group psychotherapeutic treatment 
with treatment-as-usual. On average, 38% and 34% of the treatment and control condition 
were female, respectively. The lower and upper ages of the participants ranged from 17 
years to 78 years of age and the mean age reported was 39 years; four studies did not have 
any information on age range and four studies did not state an upper limit. In total 2634 
patients were represented in the 32 data sets included in this review; of which 1334 
participants were represented in the treatment condition and 1300 were represented in the 
control condition. 
 
Risk of Bias 
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 In total, three studies scored ‘high risk of bias’ for at least four of the six categories, 
and were therefore rated as low quality (see online suppl. Fig. 2). With the exception of the 
funnel plot on positive symptoms, all plots are slightly asymmetric, with an absence of data 
in the lower right hand side of the plot (see online Fig. 3). Egger tests of publication bias 
found no statistical evidence for publication bias for negative, positive or general symptom 
scores. There was however statistical evidence for publication bias for the studies included 
in the meta-analyses comparing group therapeutic treatments with TAU and active sham 
groups for total symptoms (Beta = 0.975, P=0.01) and for studies included in the total 
symptoms planned sensitivity analyses (Beta = 0.999, P = 0.02). 
 
Impact of Group Psychotherapeutic Treatments on Symptoms 
 Table 1 summarises findings from the meta-analyses comparing group 
psychotherapeutic treatments with TAU and active sham groups,  and sensitivity analyses 
(which excluded studies with a high risk of bias and studies where baseline mean symptom 
scores varied across the treatment and control condition, see online suppl. Table 6) on end-
point outcomes for positive, negative and general symptoms.  Separate analyses were 
conducted for studies that compared a group psychotherapeutic treatment to TAU, and 
those that compared a group psychotherapeutic treatment to an active sham group.  
In the meta-analyses comparing group psychotherapeutic treatments to TAU, there 
was a significant between-group difference for end-point negative symptom scores, end-
point general symptom scores and end-point total symptom scores in favour of the 
treatment condition. No main effect was found for positive symptom scores. Findings were 
robust across planned sensitivity analyses for both negative and positive symptoms.  
However, the effect on general symptoms and total symptoms were no longer significant in 
the planned sensitivity analyses, following removal of studies rated as high risk of bias.  
Forest plots for group psychotherapeutic treatments compared to TAU and active group 
shams are shown in online suppl. Fig 4.a and 4.b respectively.  
There was no evidence for a significant between-group difference for end-point  
negative symptoms, positive symptoms, general symptoms or total symptoms for studies 
that compared a group psychotherapeutic treatment and an active sham group.  
 
(Table 1 – Meta-analyses) 
 
Meta-Regression Analysis 
 Meta-regression analyses were limited to outcomes on negative symptoms, given 
that no effect of group psychotherapeutic treatments was found on positive symptoms and 
that findings on the impact of general and total symptoms were inconsistent across the 
planned sensitivity analyses. The effect of group psychotherapeutic treatments on negative 
symptoms was not moderated by the therapeutic orientation or diagnostic homogeneity 
(see Table 2). However, the effect size on negative symptoms was positively moderated by 
the treatment intensity of the group psychotherapeutic treatments (Beta = 0.32 SE = 0.121, 
P<0.05). The adjusted R-squared value indicated that 31% of the variance in this model was 
accounted for by the intensity sessions, measured as number of sessions available in the 
group psychotherapeutic treatments. 
 
(Table 2 – Meta-regression Table) 
 
Impact of Group Psychotherapeutic Treatments on Social Functioning 
 In total, 11 of the 19 included which compared a group psychotherapeutic 
treatment with TAU, reported outcomes on social functioning; see online suppl. Table 7. Six 
of the 11 studies [7, 12, 34, 52, 58, 63] found a statistically significant improvement favoring 
the group psychotherapeutic treatments over the control condition and five studies did not 
[41, 53, 57, 59, 61]. Nine different measures of social functioning were reported in the 11 
studies. 
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Discussion 
 
This review found that group psychotherapeutic treatments were more effective in 
reducing negative symptoms than treatment-as-usual (TAU) across a diverse range of 
psychotherapeutic orientations. This effect was apparent only when these group 
psychotherapeutic treatments were compared against TAU, not active sham groups. There 
was no evidence that group psychotherapeutic treatments improved positive symptoms 
across a range of group psychotherapeutic treatments compared to TAU or active sham 
groups. Furthermore, any evidence that general symptoms and total symptoms improved in 
favour of the group psychotherapeutic treatment condition compared to TAU was no longer 
significant when eliminating studies rated as ‘high-risk’ of bias. The narrative summary of 
studies indicated that overall, participants in group psychotherapeutic treatments benefited 
more in terms of reduced social functioning deficits in the treatment condition compared to 
TAU. No evidence was found for an effect of therapeutic orientation or diagnostic 
homogeneity. However, there was a significant positive relationship between treatment 
intensity and reduced negative symptoms. 
This study has a number of strengths. It is the first systematic review to explore the 
effectiveness of psychotherapeutic treatments delivered in groups using meta-analytic 
techniques. We used rigorous methods and a wide array of search terms encompassing a 
broad range of verbal and nonverbal psychotherapeutic group treatments. Stringent 
measures controlled for study quality. For example, all studies were independently extracted 
and assessed for risk of bias. Low-quality studies were excluded in planned sensitivity 
analyses rather than being rated on a quality scale and controlled for statistically [64].   
There are also a number of potential limitations. The majority of the sample 
represented were outpatients (71%) and male (64%), which may limit generalisability.  
However, as noted by Jane-Wit and colleagues [65], an important factor contributing to 
different results between randomised controlled trials, is the difference in patient 
characteristics. Hence, the clinical validity of the findings is strengthened by the 
homogeneous population across the studies.  
There is also the possibility of publication bias. Visual examination of funnel plots 
(see online suppl Fig.3) for negative, general and total symptoms indicate that there are 
slightly fewer trials with small samples favouring the control condition represented in this 
review. This may have biased the results of the review against the control condition. To 
account for this, statistical tests of publication bias were conducted. No statistical evidence 
of publication bias was found for positive, negative or general scores. There was however 
statistical evidence for bias for total symptom scores.   
Furthermore, I² scores from meta-analyses on negative symptoms indicate a 
moderate to high level of heterogeneity; i.e. I² scores between 50-75% [32]. However, visual 
examination of the forest plots (see online suppl. Fig4.a and 4.b) indicated consistent 
overlap between the confidence intervals of the effect sizes in the majority of the studies,  
hence minimal heterogeneity between studies. It is therefore likely that the high 
heterogeneity is being driven by a minority of outliers - Vreeland et al [62] and Levine et al 
[46] in the TAU and active sham group analyses respectively  – rather than significant 
variation between studies. 
This review is also limited to symptom and social functioning outcomes. Given that 
group psychotherapeutic treatments have been implicated with a variety of improved 
outcomes [8, 22, 66], conclusions on their effectiveness are arguably therefore incomplete. 
To address this limitation, separate analyses were conducted on major symptom domains.  
Most studies were not reported as intention-to-treat analyses. Since drop out is 
unlikely to be due to random factors, and that only few studies reported reasons for drop-
out, this may introduce completer-only bias. Given that too few studies carried out an 
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intention-to-treat analysis, a further sensitivity analysis on this sub-group of studies was not 
deemed suitable. However, encouragingly, the follow-up assessment rate at end of 
treatment was high across both treatment vs active sham groups and treatment vs TAU 
comparisons.  
Finally, group psychotherapeutic treatments have not been assessed against 
individual psychotherapeutic treatments. Without controlling for the specific factors 
potentially relevant to the psychotherapeutic treatment itself, it is difficult to make firm 
conclusions about the benefits of non-specific group effects. Whilst Wykes and colleagues 
[67] found no difference in the two treatment modalities, the validity of this comparison is 
limited by the fact that only seven group CBT studies were compared to 26 studies on 
individual CBT.  
Overall, evidence from this review supports the view that group mechanisms 
underpinning different group psychotherapeutic treatments can be clinically advantageous 
for people with schizophrenia [8, 26, 66] in the treatment of negative symptoms [16] and 
social functioning deficits [11]. As argued by Kanas [66], ‘the group experience itself’ (page 
10) appears to be clinically useful for this population who are often isolated and relate 
poorly with others. Both the effectiveness of group psychotherapeutic treatments across 
different therapeutic orientations as compared to TAU, and the absence of a significant 
effect as compared to active sham groups, is consistent with the hypothesis that beneficial 
group mechanisms are non-specific [20, 26]. In support of Wampold’s [23] ‘contextual’ 
model of psychotherapy, these findings support the view that the benefit of group 
therapeutic mechanisms is due to common factors.  
The group effect is shared across different approaches and potentially also with 
sham groups, which inevitably have some group processes in common with 
psychotherapeutic groups. The fact that a group condition is meant to be a sham condition 
in a trial can be obvious to researchers, but is often not evident to participants taking part in 
the trial. With respect to sham conditions however we cannot establish whether they are 
also effective in improving negative symptoms. Whilst we did not find a difference with 
psychotherapeutic groups, the data do not allow us to test for non-inferiority, and a direct 
comparison of sham groups with TAU was not possible.  
Whilst the effect size on negative symptoms was only small-to-moderate, this effect 
is bigger than the standardised mean difference scores for negative symptoms reported in 
meta-analyses of CBT for schizophrenia [64]. Furthermore, the effect size is comparable with 
the effect sizes in studies of social skills training for schizophrenia [68], cognitive 
remediation therapy on overall symptoms of schizophrenia [69] and scores from meta-
analyses of first and second generation anti-psychotics [70].  
In contrast to Segredou and colleagues’ [8] review on group psychotherapeutic 
treatments for schizophrenia, there was no evidence for improved positive symptoms. The 
inclusion of nonverbal therapies and more precise statistical techniques may account for this 
difference. Furthermore, results from this review are not consistent with the notion that 
group processes can be effective in aiding the restructuring of false beliefs around delusions 
or hallucinations [15, 71] in the treatment of positive symptoms [20, 23, 26]. As suggested 
by Wykes and colleagues [7], it might be difficult for therapists to flexibly respond to a wide 
variety of individual therapeutic needs when addressing positive symptoms in groups. Hence 
a ‘group effect’ for positive symptoms might be specific only for highly homogenous groups,  
such as Hearing Voices groups [14], rather than a non-specific shared effect [23].  
 In the meta-regression analyses there was no evidence that the ‘therapeutic 
orientation’, in terms of arts vs non-arts and CBT vs non-CBT studies, moderated the group 
effect on negative symptoms. This supports the idea that the benefit of group  
psychotherapeutic treatments, in terms of negative symptoms at least, is independent of a 
particular therapeutic approach [20]. Furthermore, there was no evidence to suggest that 
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the degree of ‘diagnostic homogeneity’ moderated the effect of group psychotherapeutic 
treatments on negative symptoms. Therefore the non-specific effect of negative symptoms 
held true for groups consisting of patients with a diagnosis of schizophrenia and related 
disorders [10]. However, the more ‘intense’ treatments were related to a greater difference 
in negative symptom scores. This supports the hypothesis that longer group 
psychotherapeutic treatments for schizophrenia are more effective than shorter treatments 
[22]. This result further refines the importance of ‘length’ of treatment to ‘number of 
sessions in a given space of time’ [72] as a more precise factor that may influence the 
effectiveness of this treatment modality [22]. Effective group mechanisms may therefore 
have a dose-response association, where short-term groups with few sessions do not 
exhaust the full potential of these mechanisms.  
In conclusion, findings from this review suggest that group psychotherapeutic 
therapies, irrespective of their therapeutic approach, can improve negative symptoms and 
social functioning deficits in the treatment of schizophrenia. In support of the contextual 
model of psychotherapy, the impact of group mechanisms on negative symptoms appear to 
be non-specific and shared across a wide range of psychotherapeutic treatments delivered 
in a group setting. Future research should identify the non-specific mechanisms that explain 
the effect of group participation on negative symptoms and explore ways to strengthen 
them so that the therapeutic benefit is maximised.   
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Table 1. Summary of meta-analyses for positive, negative, general and total symptom scores, comparing group 
psychotherapeutic treatments against treatment-as-usual and active sham groups 
 
Outcome 
 
 
Analysis 
 
Number of 
studies 
 
 
Number of 
participants 
 
SMD (95% CI) 
 
P value 
 
I² (%) 
       
Negative 
Symptoms 
Treatment vs TAU 15 893 -0.37 (-0.60, -0.14) 0.002 59.8 
Treatment vs Sham 12 783 -0.09 (-0.36, 0.19) 0.542 68.5 
Sensitivity (Treatment vs TAU) 12 762 -0.40(-0.67, -0.13) 0.004 66.6 
 Sensitivity (Treatment vs Sham) 10 687 -0.09 (-0.33, 0.16) 0.504 56.3 
       
Positive 
Symptoms 
Treatment vs TAU 11 730 -0.06 (-0.25, 0.13) 0.553 29.8 
Treatment vs Sham 9 654 0.07 (-0.32, 0.18) 0.590 49.7 
Sensitivity (Treatment vs TAU) 8 654 -0.02 (-0.21, 0.18) 0.877 27.5 
 Sensitivity (Treatment vs Sham) 9 654 0.07 (-0.32, 0.18) 0.590 49.7 
       
General 
Symptoms 
Treatment vs TAU 9 625 -0.22 (-0.43, -0.02) 0.035 27.8 
Treatment vs Sham 6 521 0.17 (-0.76, 0.42) 0.575 87.9 
Sensitivity (Treatment vs TAU) 7 593 -0.13 (-0.29, -0.03) 0.120 0 
 Sensitivity (Treatment vs Sham) 4 425 -0.16 (-0.46, 0.14) 0.303 49.8 
       
Total 
Symptoms 
Treatment vs TAU 9 651 -0.41 (-0.69, -0.13) 0.004 60.3 
Treatment vs Sham 10 812 0.12 (-0.74, 0.35) 0.479 91.8 
Sensitivity (Treatment vs TAU) 5 514 -0.33 (-0.66, 0.01) 0.052 66.3 
 Sensitivity (Treatment vs Sham) 8 538 -0.48 (-1.10, 0.11) 0.108 88.5 
NB: Treatment vs TAU = meta-analysis comparing group psychotherapeutic treatments with treatment-as-usual, waitlist 
control or standard psychiatric care; Treatment vs Sham = meta-analysis comparing group psychiatric treatments with active 
sham groups; Sensitivity = sensitivity analysis; SMD = Standardized Mean Differences; CI = Confidence Intervals; I² = 
heterogeneity 
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Table 2. Summary of meta-regression analysis on end-point negative symptom standardised mean difference 
scores comparing group psychotherapeutic treatments and TAU 
 
Characteristic 
 
 
Coef. 
 
SE 
 
I² (%) 
 
 
Adjusted 
R² (%) 
 
P value 
 
Therapeutic Orientation: Arts & 
Others 
 
 
0.220 
 
 
0.201 
 
61.39 
 
-1.41 
 
0.282 
      
Therapeutic Orientation: Cognitive-
Behavioural & Others 
-0.004 0.185 63.46 -6.20 0.985 
      
Intensity (log transformed) 0.320 0.121 55.10 31.02 0.014 
      
Diagnostic Homogeneity 
 
-0.001 0.176 61.65 -6.94 0.994 
Note: TAU = treatment as usual, Coef. = coefficient, SE = Standard Error, Adjusted R²= variance, I² = heterogeneity 
 
 
 
